Introduction Stage III colon cancer is traditionally treated with adjuvant oxaliplatin-based chemotherapy such as FOLFOX. However, tumours with mismatch repair deficiency (dMMR) represent a biologically distinct subgroup with high immunogenicity and responsiveness to immune checkpoint inhibition in metastatic settings.
Introduction
Stage III colon cancer is traditionally treated with adjuvant oxaliplatin-based chemotherapy such as FOLFOX. However, tumours with mismatch repair deficiency (dMMR) represent a biologically distinct subgroup with high immunogenicity and responsiveness to immune checkpoint inhibition in metastatic settings. Whether this immunotherapy benefit can be translated into the curative, adjuvant setting has remained a critical unanswered question. The ATOMIC trial addresses this gap by evaluating the addition of atezolizumab, a PD-L1 inhibitor, to standard mFOLFOX6 in resected stage III dMMR colon cancer.
Problem Statement
Despite standard adjuvant chemotherapy, recurrence rates in high-risk stage III colon cancer remain significant. dMMR tumours, although prognostically favourable in early stages, still demonstrate recurrence risk in stage III disease. The key clinical challenge has been whether incorporating immunotherapy early—before recurrence—can meaningfully improve disease-free survival and potentially cure rates.
Summary
In this phase III trial, adding atezolizumab to mFOLFOX6 significantly improved outcomes. At a median follow-up of 40.9 months, 3-year disease-free survival was 86.3% in the combination group compared to 76.2% with chemotherapy alone, translating to a 50% reduction in recurrence or death risk. This represents one of the first strong pieces of evidence supporting immunotherapy in the adjuvant setting for colon cancer. However, this benefit came with increased grade 3–4 adverse events (84.1% vs 71.9%), highlighting the need for careful patient selection.
Overall, this study marks a major step toward precision oncology in early-stage colon cancer, potentially redefining the standard of care for stage III dMMR disease.
Introduction: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for monitoring treatment response and residual disease in solid tumors. However, its prognostic value during neoadjuvant chemotherapy (NAC) for localized pancreatic ductal adenocarcinoma...
Introduction: Aspirin is one of the few interventions proven to reduce colorectal and other Lynch syndrome–associated cancers. The earlier CaPP2 trial established 600 mg daily aspirin as an effective chemopreventive strategy, but concerns regarding long-term...
Introduction: The TOPAZ-1 trial established durvalumab combined with gemcitabine and cisplatin (GemCis) as the first immunotherapy-based first-line standard of care for advanced biliary tract cancer (BTC). However, long-term survival outcomes and durability of benefit beyond...
Introduction: Somatostatin receptor (SSTR) PET/CT has become indispensable for diagnosing, staging, and monitoring neuroendocrine tumors (NETs). However, until now, there has been no standardized method for assessing treatment response using SSTR PET imaging. This international...
Introduction: Staging laparoscopy (SL) is recommended for patients with locally advanced gastric cancer to detect occult peritoneal metastases before curative treatment. However, its real-world utilization across Europe remains uncertain. This large GASTRODATA study evaluated the...
Introduction: Neoadjuvant immune checkpoint inhibitors have transformed the management of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer, achieving unprecedented pathological response rates. Experimental evidence suggests that cyclooxygenase-2 (COX-2) inhibition may enhance...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.